Leon Moulder Jr Acquires 20,000 Shares of Zenas BioPharma (NASDAQ:ZBIO) Stock

Zenas BioPharma, Inc. (NASDAQ:ZBIO) CEO Leon Moulder, Jr. purchased 20,000 shares of the stock in a transaction on Friday, January 9th. The stock was acquired at an average cost of $16.55 per share, for a total transaction of $331,000.00. Following the acquisition, the chief executive officer directly owned 366,155 shares in the company, valued at approximately $6,059,865.25. This trade represents a 5.78% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Zenas BioPharma Price Performance

Zenas BioPharma stock traded down $0.33 during trading hours on Friday, hitting $16.08. 529,200 shares of the stock were exchanged, compared to its average volume of 981,324. The company has a debt-to-equity ratio of 0.37, a quick ratio of 5.66 and a current ratio of 5.66. The stock has a market capitalization of $863.17 million, a P/E ratio of -2.27 and a beta of -1.45. The business’s 50-day moving average is $34.94 and its two-hundred day moving average is $24.01. Zenas BioPharma, Inc. has a 12 month low of $5.83 and a 12 month high of $44.60.

Zenas BioPharma (NASDAQ:ZBIO) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($1.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.35).

Analyst Upgrades and Downgrades

Several brokerages recently commented on ZBIO. Morgan Stanley downgraded Zenas BioPharma from an “overweight” rating to an “equal weight” rating and dropped their price objective for the stock from $37.00 to $19.00 in a research note on Monday. HC Wainwright reaffirmed a “buy” rating on shares of Zenas BioPharma in a research report on Tuesday, December 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Zenas BioPharma in a research report on Monday, December 29th. Jefferies Financial Group restated a “buy” rating and set a $48.00 target price on shares of Zenas BioPharma in a report on Tuesday. Finally, Wall Street Zen upgraded shares of Zenas BioPharma from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Zenas BioPharma presently has an average rating of “Moderate Buy” and an average price target of $43.14.

Institutional Trading of Zenas BioPharma

Hedge funds and other institutional investors have recently modified their holdings of the stock. Federated Hermes Inc. raised its holdings in Zenas BioPharma by 60.8% in the 2nd quarter. Federated Hermes Inc. now owns 1,861,838 shares of the company’s stock valued at $18,041,000 after acquiring an additional 703,838 shares during the period. Vanguard Group Inc. boosted its stake in Zenas BioPharma by 17.2% in the 3rd quarter. Vanguard Group Inc. now owns 1,162,758 shares of the company’s stock valued at $25,813,000 after purchasing an additional 170,546 shares during the period. Geode Capital Management LLC grew its holdings in Zenas BioPharma by 4.6% in the 2nd quarter. Geode Capital Management LLC now owns 373,617 shares of the company’s stock valued at $3,621,000 after buying an additional 16,461 shares in the last quarter. Invesco Ltd. bought a new position in Zenas BioPharma during the 3rd quarter worth $3,237,000. Finally, Millennium Management LLC acquired a new stake in shares of Zenas BioPharma during the third quarter worth $1,595,000.

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.